Dianhydrogalactitol - DelMar Pharmaceuticals

Drug Profile

Dianhydrogalactitol - DelMar Pharmaceuticals

Alternative Names: DAG for Injection; Dianhydrodulcitol; Diepoxydulcitol; Diepoxygalactitol; NSC-1323313; VAL-083

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DelMar Pharmaceuticals
  • Developer DelMar Pharmaceuticals; Guangxi Wuzhou Pharmaceutical; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Epoxy compounds; Ethylene glycols; Small molecules
  • Mechanism of Action Alkylating agents; Cell cycle inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Ovarian cancer; Medulloblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Lung cancer
  • Phase III Glioblastoma
  • Preclinical Medulloblastoma; Ovarian cancer
  • No development reported Haematological malignancies; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Haematological-malignancies in USA (IV, Infusion)
  • 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Solid-tumours in USA (IV, Infusion)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top